Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1981 1
1987 1
1989 2
1990 1
1991 1
1993 4
1995 4
1996 5
1997 4
1998 7
1999 3
2000 5
2001 7
2002 11
2003 13
2004 14
2005 10
2006 19
2007 23
2008 31
2009 47
2010 57
2011 59
2012 71
2013 64
2014 67
2015 78
2016 59
2017 50
2018 66
2019 65
2020 72
2021 57
2022 57
2023 48
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

932 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, Jeong J, Kim A, Park KH, Sasano H, Ohashi Y, Toi M. Masuda N, et al. N Engl J Med. 2017 Jun 1;376(22):2147-2159. doi: 10.1056/NEJMoa1612645. N Engl J Med. 2017. PMID: 28564564 Free article. Clinical Trial.
Among patients with triple-negative disease, the rate of disease-free survival was 69.8% in the capecitabine group versus 56.1% in the control group (hazard ratio for recurrence, second cancer, or death, 0.58; 95% CI, 0.39 to 0.87), and the overall survival rate was 78.8% versus …
Among patients with triple-negative disease, the rate of disease-free survival was 69.8% in the capecitabine group versus 56.1% in the contr …
Hand-foot syndrome induced by chemotherapy drug: Case series study and literature review.
Zaiem A, Hammamia SB, Aouinti I, Charfi O, Ladhari W, Kastalli S, Aidli SE, Lakhoua G. Zaiem A, et al. Indian J Pharmacol. 2022 May-Jun;54(3):208-215. doi: 10.4103/ijp.ijp_175_21. Indian J Pharmacol. 2022. PMID: 35848692 Free PMC article. Review.
INTRODUCTION: Chemotherapy drugs can be responsible of several side effects such as hand-foot syndrome (HFS). This syndrome is also called "palmar-plantar erythrodysesthesia" and "acral erythema." ...
INTRODUCTION: Chemotherapy drugs can be responsible of several side effects such as hand-foot syndrome (HFS). This synd …
Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study).
Santhosh A, Kumar A, Pramanik R, Gogia A, Prasad CP, Gupta I, Gupta N, Cheung WY, Pandey RM, Sharma A, Batra A. Santhosh A, et al. Trials. 2022 May 19;23(1):420. doi: 10.1186/s13063-022-06353-2. Trials. 2022. PMID: 35590388 Free PMC article. Clinical Trial.
INTRODUCTION: Hand-foot syndrome (HFS) is a common cutaneous side effect of capecitabine therapy. ...The secondary objective is to compare the effect of topical diclofenac with placebo on preventing all grades of HFS (incidence of NCI CTCv5.0 all grade HFS), …
INTRODUCTION: Hand-foot syndrome (HFS) is a common cutaneous side effect of capecitabine therapy. ...The secondary obje …
Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management.
Miller KK, Gorcey L, McLellan BN. Miller KK, et al. J Am Acad Dermatol. 2014 Oct;71(4):787-94. doi: 10.1016/j.jaad.2014.03.019. Epub 2014 May 1. J Am Acad Dermatol. 2014. PMID: 24795111 Review.
Chemotherapy-induced hand-foot syndrome and nail changes are common complications of many classic chemotherapeutic agents and the newer molecular targeted therapies. ...
Chemotherapy-induced hand-foot syndrome and nail changes are common complications of many classic chemotherapeutic agen …
Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials.
Pandy JGP, Franco PIG, Li RK. Pandy JGP, et al. Support Care Cancer. 2022 Nov;30(11):8655-8666. doi: 10.1007/s00520-022-07175-3. Epub 2022 Jun 2. Support Care Cancer. 2022. PMID: 35655045 Review.
PURPOSE: Hand-foot syndrome (HFS) and hand-foot skin reaction (HFSR) are common toxicities of several systemic cancer treatments. ...
PURPOSE: Hand-foot syndrome (HFS) and hand-foot skin reaction (HFSR) are common toxicities of several systemic cancer t …
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial.
Wang X, Wang SS, Huang H, Cai L, Zhao L, Peng RJ, Lin Y, Tang J, Zeng J, Zhang LH, Ke YL, Wang XM, Liu XM, Chen QJ, Zhang AQ, Xu F, Bi XW, Huang JJ, Li JB, Pang DM, Xue C, Shi YX, He ZY, Lin HX, An X, Xia W, Cao Y, Guo Y, Su YH, Hua X, Wang XY, Hong RX, Jiang KK, Song CG, Huang ZZ, Shi W, Zhong YY, Yuan ZY; South China Breast Cancer Group (SCBCG). Wang X, et al. JAMA. 2021 Jan 5;325(1):50-58. doi: 10.1001/jama.2020.23370. JAMA. 2021. PMID: 33300950 Free PMC article. Clinical Trial.
In the capecitabine group vs the observation group, the estimated 5-year distant disease-free survival was 85.8% vs 75.8% (HR for risk of distant metastasis or death, 0.60 [95% CI, 0.38-0.92]; P = .02), the estimated 5-year overall survival was 85.5% vs 81.3% (HR for risk of deat …
In the capecitabine group vs the observation group, the estimated 5-year distant disease-free survival was 85.8% vs 75.8% (HR for risk of di …
Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial.
Santhosh A, Sharma A, Bakhshi S, Kumar A, Sharma V, Malik PS, Pramanik R, Gogia A, Prasad CP, Sehgal T, Gund S, Dev A, Cheung WY, Pandey RM, Kumar S, Gupta I, Batra A; D-TORCH Trial Investigators. Santhosh A, et al. J Clin Oncol. 2024 May 20;42(15):1821-1829. doi: 10.1200/JCO.23.01730. Epub 2024 Feb 27. J Clin Oncol. 2024. PMID: 38412399 Clinical Trial.
PURPOSE: Hand-foot syndrome (HFS) is a dose-limiting side effect of capecitabine. ...
PURPOSE: Hand-foot syndrome (HFS) is a dose-limiting side effect of capecitabine. ...
Capecitabine and hand-foot syndrome.
Saif MW. Saif MW. Expert Opin Drug Saf. 2011 Mar;10(2):159-69. doi: 10.1517/14740338.2011.546342. Epub 2010 Dec 22. Expert Opin Drug Saf. 2011. PMID: 21174613 Review.
Hand-foot syndrome (HFS), or palmar-plantar erythrodysesthesia, is a common side effect in patients taking long-term 5-fluorouracil treatment and is the most frequently reported side effect of oral capecitabine therapy ( 50% of patients). ...
Hand-foot syndrome (HFS), or palmar-plantar erythrodysesthesia, is a common side effect in patients taking long-term 5- …
Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD.
de With M, van Doorn L, Maasland DC, Mulder TAM, Oomen-de Hoop E, Mostert B, Homs MYV, El Bouazzaoui S, Mathijssen RHJ, van Schaik RHN, Bins S. de With M, et al. Biomed Pharmacother. 2023 Mar;159:114232. doi: 10.1016/j.biopha.2023.114232. Epub 2023 Jan 9. Biomed Pharmacother. 2023. PMID: 36630849 Free article.
AIM OF THE STUDY: Occurrence of hand-foot syndrome (HFS) during capecitabine treatment often results in treatment interruptions (26 %) or treatment discontinuation (17 %), and can severely decrease quality of life. ...
AIM OF THE STUDY: Occurrence of hand-foot syndrome (HFS) during capecitabine treatment often results in treatment inter …
932 results